U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C83H141IN22O23.2O.Tc
Molecular Weight 2072.9508
Optical Activity UNSPECIFIED
Defined Stereocenters 13 / 13
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of NC-100668 TC-99m

SMILES

[O--].[O--].[99Tc+4].CCC(C)(C)NCCN(CCNC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC(I)=C(O)C=C1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(C)=O)C(C)C)[C@@H](C)O)CCNC(C)(C)C(\C)=N\O

InChI

InChIKey=NAEQGNBDGQRREM-ACJRLMHLSA-N
InChI=1S/C83H141IN22O23.2O.Tc/c1-15-82(11,12)91-31-35-105(36-32-92-83(13,14)48(9)104-129)34-30-89-66(114)42-90-70(117)52(19-16-17-29-85)94-74(121)56(37-44(2)3)98-75(122)57(38-45(4)5)100-80(127)69(47(8)108)103-77(124)58(40-50-21-25-62(110)51(84)39-50)99-78(125)61-20-18-33-106(61)81(128)60(43-107)101-79(126)68(46(6)7)102-73(120)54(23-27-64(87)112)95-72(119)55(24-28-67(115)116)96-71(118)53(22-26-63(86)111)97-76(123)59(41-65(88)113)93-49(10)109;;;/h21,25,39,44-47,52-61,68-69,91-92,107-108,110,129H,15-20,22-24,26-38,40-43,85H2,1-14H3,(H2,86,111)(H2,87,112)(H2,88,113)(H,89,114)(H,90,117)(H,93,109)(H,94,121)(H,95,119)(H,96,118)(H,97,123)(H,98,122)(H,99,125)(H,100,127)(H,101,126)(H,102,120)(H,103,124)(H,115,116);;;/q;2*-2;+4/b104-48+;;;/t47-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,68+,69+;;;/m1.../s1/i;;;1+1

HIDE SMILES / InChI

Molecular Formula O
Molecular Weight 15.9994
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C83H141IN22O23
Molecular Weight 1942.0457
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 13 / 13
E/Z Centers 1
Optical Activity UNSPECIFIED

Molecular Formula Tc
Molecular Weight 98.906254554
Charge 4
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Tue Apr 01 18:44:17 GMT 2025
Edited
by admin
on Tue Apr 01 18:44:17 GMT 2025
Record UNII
R8S6NAJ6P8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
(4S)-4-(((2S)-2-(((2S)-2-ACETAMIDO-4-AMINO-4-OXO-BUTANOYL)AMINO)-5-AMINO-5-OXO-PENTANOYL)AMINO)-5-(((1S)-4-AMINO-1-(((1S)-1-(((1S)-2-((2S)-2-(((1S)-2-(((1S)-1-(((1S)-1-(((1S)-1-(((1S)-5-AMINO-1-((2-(2-(BIS(2-(((2E)-2-HYDROXYIMINO-1,1-DIMETHYL-PROPYL)AMIN
Preferred Name English
NC-100668 TC-99m
Code English
NC100668 TC-99m
Code English
99mTc-NC100668
Code English
Code System Code Type Description
FDA UNII
R8S6NAJ6P8
Created by admin on Tue Apr 01 18:44:17 GMT 2025 , Edited by admin on Tue Apr 01 18:44:17 GMT 2025
PRIMARY
PUBCHEM
169490713
Created by admin on Tue Apr 01 18:44:17 GMT 2025 , Edited by admin on Tue Apr 01 18:44:17 GMT 2025
PRIMARY
Related Record Type Details
NON-LABELED -> LABELED
TARGET->MIMETIC
TARGET->RADIOLIGAND
Related Record Type Details
ACTIVE MOIETY
(99m)Tc-NC100668 was rapidly absorbed into and retained by blood clots and was not significantly affected by the presence of unfractionated or low molecular weight heparin or thrombin inhibitor. Tissue plasminogen activator reduced the uptake of (99m)Tc-NC100668 into blood clot by a factor of 3 when adjusted to allow for changes in the weight of the blood clot. This study has demonstrated that the uptake and retention of (99m)Tc-NC100668 into blood clots in the rat model of deep vein thrombosis is rapid and maintained over at least a 4 h. post-injection period. It has been shown that (99m)Tc-NC100668 is retained in blood clots even in the presence of therapeutic doses of those anticoagulant and thrombolytic therapies typically used to treat pulmonary embolism and venous thrombosis.